Amarantus, a biotechnology company developing diagnostics in neurology and orphan drugs in neurology, ophthalmology, psychiatry and regenerative medicine, recently announced their abstract “The LymPro® Assay: A Biomarker For Alzheimer’s Disease Using Blood Samples From Clinically Diagnosed Alzheimer’s Disease And Cognitively Intact Subjects” has been accepted for poster presentation at the 12th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders. The conference will be held in Nice, France on March 18-22, 2015. The poster will be presented by Louis Kirby, Amarantus’ representative.
The poster will cover positive blood sample analyses of 140 individuals using Amarantus’ LymPro Test, a blood-based assay indicated for Alzheimer’s disease. Enrollees in the LymPro Test’s clinical trial included 71 Alzheimer’s patients and 69 controls without the disease, all within the same age range. The company’s test measures the lymphocyte proliferation that results from the response to a mitogenic stimulus and then quantifies the extent to which lymphocytes have started their cell division cycle.
A crucial pathology in Alzheimer’s is related to the cell cycle dysregulation in neurons, which results in cognitive decline caused by neuronal death. The LymPro test uses the lymphocyte measurements as a sort of analogy of this neuronal cell dysfunction. Combined with standard of care clinical measurements, the LymPro test can provide physicians with greater confidence that an Alzheimer’s diagnosis is accurate.
“We are very pleased to have this confirmatory LymPro abstract accepted for a poster session at one of the premiere scientific congresses focused on neurological disorders. We believe the LymPro Test is an important leading Alzheimer’s biomarker assay and is a key diagnostic asset for advancing robust therapeutic clinical studies in Alzheimer’s disease. This conference will provide important exposure as we continue building a significant customer base for blood-based biomarker services in Alzheimer’s disease, with the ultimate shared goal of improving the current standard of care used to treat AD,” said Gerald Commissiong, the CEO & President of Amarantus BioSciences Holdings, Inc.
Alzheimer’s disease affects more than 5.4 million people in the United States alone, according to the Alzheimer’s Association. More than 500,000 are diagnosed with the disease each year, which emphasizes the importance of research in the field and in particular the relevance of this project.